Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 32, Number 7—July 2026
Research
National Surveillance of Enterovirus D68 Upsurge, France, 2024
Marion Jeannoël, Maxime Bisseux, Stéphanie Dan, Elisa Creuzet, Delphine Parraud, Jean-Luc Bailly, Jérémie Lebeurre, Amélie Brebion, Hélène Chabrolles, Laurence Josset, Cécile Henquell, Isabelle Schuffenecker, Audrey Mirand
, and Enterovirus Surveillance Network1
, and Enterovirus Surveillance Network1
Table 2
Clinical characteristics of cases in study of enterovirus D68 upsurge, France, 2024*
| Characteristic | Children 0–17 y, n = 363 |
Adults >18 y, n = 289 |
Total, N = 652 |
|||||
|---|---|---|---|---|---|---|---|---|
| No. (%) patients | No. (%) severity criteria | No. (%) patients | No. (%) severity criteria | No. (%) patients | No. (%) severity criteria | |||
| Respiratory symptoms | 332 (91.5) | 91 (25.1) | 278 (96.2) | 55 (19.0) | 610 (93.6) | 146 (22.4) | ||
| URTI | 100 (27.5) | 3 (0.8) | 81 (28.0) | 0 | 181 (27.8) | 3 (0.5) | ||
| Asthma | 147 (40.5) | 61 (16.8) | 33 (11.4) | 11 (3.8) | 180 (27.6) | 72 (11.0) | ||
| Bronchiolitis, bronchitis, bronchial syndrome | 45 (12.4) | 12 (3.3) | 24 (8.3) | 0 | 69 (10.6) | 12 (1.8) | ||
| Pneumonia | 18 (5.0) | 4 (1.1) | 52 (18.0) | 15 (5.2) | 70 (10.7) | 19 (2.9) | ||
| Dyspnea | 5 (1.4) | 0 | 15 (5.2) | 0 | 20 (3.1) | 0 | ||
| Neonatal apnea/distress | 3 (0.8) | 0 | NA | NA | 3 (0.5) | 0 | ||
| Acute exacerbation of COPD | NA | NA | 41 (14.2) | 12 (4.2) | 41 (6.3) | 12 (1.8) | ||
| Respiratory distress |
15 (4.1) |
7 (1.9) |
31 (10.7) |
17 (5.9) |
46 (7.1) |
24 (3.7) |
||
| Neurologic symptoms | 17 (4.7) | 7 (1.9) | 5 (1.7) | 4 (1.4) | 22 (3.4) | 11 (1.7) | ||
| Seizures | 14 (3.9) | 7 (1.9) | 1 (0.3) | 0 | 15 (2.3) | 7 (1.1) | ||
| Encephalitis | 4 (1.1) | 4 (1.1) | 0 | 0 | 4 (0.6) | 4 (0.6) | ||
| Meningitis | 1 (0.3) | 0 | 0 | 0 | 1 (0.2) | 0 | ||
| Myelitis, Guillain-Barré syndrome | 0 | 0 | 4 (1.4) | 4 (1.4) | 4 (0.6) | 4 (0.6) | ||
| Other |
1 (0.3)† |
0 |
0 |
0 |
1 (0.2) |
0 |
||
| Cardiovascular symptoms | 2 (0.6) | 2 (0.6) | 21 (7.3) | 14 (4.8) | 23 (3.5) | 16 (2.5) | ||
| Decompensated heart failure | 1 (0.3) | 1 (0.3) | 15 (5.2) | 7 (2.4) | 16 (2.5) | 8 (1.2) | ||
| Myocarditis | 1 (0.3) | 1 (0.3) | 0 | 0 | 1 (0.2) | 1 (0.2) | ||
| Sepsis, shock |
0 |
0 |
12 (4.2) |
11 (3.8) |
12 (1.8) |
11 (1.7) |
||
| Enteric symptoms | 57 (15.7)‡ | 0 | 25 (8.7)‡ | 0 | 82 (12.6) | 0 | ||
| Isolated fever | 6 (1.7) | 0 | 7 (2.4) | 0 | 13 (2.0) | 0 | ||
*A given patient may experience >1 clinical item. COPD, chronic obstruction pulmonary disease; NA, not applicable; URTI, upper respiratory tract infection. †Irritability and hypotonia. ‡Acute gastroenteric symptoms were the only clinical signs in 9 children and 2 adults.
1Additional members of Enterovirus Surveillance Network who contributed data are listed at the end of this article.
Page created: April 30, 2026
Page updated: June 04, 2026
Page reviewed: June 04, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.